{{Drugbox
| verifiedrevid = 447926670
| IUPAC_name = 2-(7-chloro-1,8-naphthyridin-2-yl)-3-[2-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl]-3''H''-isoindol-1-one
| image = Pazinaclone.svg
| width = 200

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 103255-66-9
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 59743
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 53893
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = MHK03047IJ
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D05378
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI =
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 2107504

<!--Chemical data-->
| C=25 | H=23 | Cl=1 | N=4 | O=4 
| molecular_weight = 478.928 g/mol
| smiles = Clc1nc2nc(ccc2cc1)N4C(=O)c3ccccc3C4CC(=O)N6CCC5(OCCO5)CC6
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C25H23ClN4O4/c26-20-7-5-16-6-8-21(28-23(16)27-20)30-19(17-3-1-2-4-18(17)24(30)32)15-22(31)29-11-9-25(10-12-29)33-13-14-34-25/h1-8,19H,9-15H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = DPGKFACWOCLTCA-UHFFFAOYSA-N
}}

'''Pazinaclone''' ('''DN-2327''') is a [[sedative]] and [[anxiolytic]] drug in the [[cyclopyrrolone]] family of drugs. Some other cyclopyrrolone drugs include [[zopiclone]] and [[eszopiclone]].

Pazinaclone has a very similar pharmacological profile to the [[benzodiazepine]]s including sedative and anxiolytic properties, but with less [[amnestic]] effects,<ref>Wada T, Fukuda N. Effect of a new anxiolytic, DN-2327, on learning and memory in rats. Pharmacology, Biochemistry and Behavior. 1992 Mar;41(3):573-9.</ref> and at low doses it is a relatively selective anxiolytic, with sedative effects only appearing at higher doses.<ref>Suzuki M, Uchiumi M, Murasaki M. A comparative study of the psychological effects of DN-2327, a partial benzodiazepine agonist, and alprazolam. Psychopharmacology. 1995 Oct;121(4):442-50.</ref>

Pazinaclone produces its sedative and anxiolytic effects by acting as a [[partial agonist]] at [[GABAA receptor|GABA<sub>A</sub>]] benzodiazepine receptors, although pazinaclone is more subtype-selective than most benzodiazepines.<ref>Atack JR. The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Expert Opinion on Investigational Drugs. 2005 May;14(5):601-18.</ref>

==Synthesis==
[[File:Pazinaclone synthesis.png|thumb|center|500px|Pazinaclone synthesis: {{US patent|4778801}}]]
Reaction of 2-amino-7-chloro-1,8-[[naphthyridine]] with [[phthalic anhydride]] leads to the corresponding phthalimide. Selective reduction of one of the imide carbonyl groups in essence converts that to an aldehyde. Condensation with ''tert''-butyl(triphenylphosphoranylidene)acetate gives the Wittig product.

The carboxylic acid is then treated with diethyl cyanophosphonate to convert that to an activated acid cyanide; reaction with 1,4-dioxa-8-azaspiro[4.5]decane results in formation of the corresponding amide, pazinaclone.

==See also==
*[[Pagoclone]]

== References ==
{{Reflist}}

{{Hypnotics and sedatives}}
{{GABAAR PAMs}}

[[Category:Cyclopyrrolones]]
[[Category:Sedatives]]
[[Category:Isoindolines]]
[[Category:Lactams]]
[[Category:Acetamides]]
[[Category:Naphthyridines]]
[[Category:GABAA receptor positive allosteric modulators]]